Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
High-Dose Vitamin D for Toxic Erythema of Chemotherapy and Related Cancer Skin Reactions
Description
The speaker discusses growing use of vitamins and micronutrients in cancer care, focusing on high-dose vitamin D as a treatment for toxic erythema of chemotherapy (TEC) and related skin injuries. Based on prior work in sunburns and nitrogen mustard skin injury, vitamin D appears to act as an immunomodulator that reduces inflammation, lowers TNF-alpha and oxidative stress, and enhances autophagy to speed skin repair. In a small prospective inpatient series of patients receiving myeloablative chemotherapy, high-dose vitamin D (roughly 100,000 to 200,000 units, sometimes with repeat dosing) plus topical steroids led to rapid improvement, including resolution of erythema and erosive lesions within days and near-normal histology later on. The talk also reviews safety data, noting that very high-dose vitamin D has not been linked to worse outcomes in cancer patients and may reduce mortality in critically ill patients, suggesting it is generally safe. The speaker now commonly uses about 200,000 units for TEC, rarely relies on systemic steroids or IVIG, and is cautious about steroids in patients on immunotherapy. A clinical trial is planned to study vitamin D for chronic hand-foot syndrome from agents like capecitabine/Xeloda, with the goal of defining better dosing and duration.
View moreConclusions
- High-dose oral vitamin D appears to rapidly reduce inflammation and improve clinical and histologic recovery in toxic erythema of chemotherapy.
- The apparent benefit of vitamin D in skin injury is likely related to immunomodulatory effects, including reduced inflammatory signaling and enhanced autophagy-mediated repair.
- In hospitalized patients with severe chemotherapy-related eruptions, high-dose vitamin D was associated with quick symptom improvement and was used as a steroid-sparing approach.
- Available evidence suggests high-dose vitamin D is generally safe, with studies in critically ill and cancer patients not showing worse overall mortality.
- In critically ill patients, vitamin D supplementation may reduce mortality, although it does not clearly shorten hospital, ICU, or ventilation duration.
- In cancer populations, vitamin D has not been associated with increased cancer-specific mortality and may be linked to better outcomes in some settings.
- The optimal dose and duration of vitamin D for these indications remain uncertain.
- Further prospective, controlled trials are needed, especially for chronic hand-foot syndrome and other non-acute chemotherapy-related toxicities.
- Scott JE, Das LM, Ahsanuddin S, Qiu Y, Binko AM, Traylor ZP, Debanne SM, Cooper KD, Boxer R, Lu KQ. Oral Vitamin D Rapidly Attenuates Inflammation from Sunburn: An Interventional Study. J Invest Dermatol. 2017 Oct;137(10):2078-2086. doi:10.1016/j.jid.2017.04.040. PMID: 28576736; PMCID: PMC5610950.#10.1016/j.jid.2017.04.040
- Das LM, Scott JE, et al. Autophagy. 2019 May;15(5):813-826.
- Ernst et al. JCI Insight. 2023 Jan;8(2):e163789.
- Nguyen et al. JAMA Dermatol. 2023 Feb;159(2):219-222.
- Putzu et al. J Crit Care. 2017;38:109-114.
- Vaughan-Shaw PG. Br J Cancer. 2020;123(11):1705-1712.